Zydus Life Science

Indicators

9 bullish · 5 neutral · 7 bearish

Verdict

Revenue crosses ₹80,000 Cr in Q1 FY27 driven by dominant consumer brands, while margin compression and currency headwinds pressure profitability.

Why

• •Consolidated revenue grew from ₹65,737 Cr in Q1 FY26 to ₹80,170 Cr in Q1 FY27, fueled by unchallenged market leadership in consumer wellness brands like Glucon-D and Sugar Free.
• •Gross margins improved to 74.0% in Q4 FY26, but EBITDA margins compressed to 24.1% in Q1 FY27 as rising operating expenses and accelerated R&D investments absorb top-line gains.
• •North America remains the largest revenue contributor at 40% in Q4 FY26, though its sales share dropped sharply to 10% in Q1 FY27, reflecting a strategic portfolio mix shift.
• •Net debt climbed to ₹43,050 Cr in Q4 FY26 and forex losses widened to ₹6,449 Cr, highlighting currency volatility and increased leverage amid scaled-back capital expenditure.

Signals